Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lymphoma 1

Interventions

Cyclophosphamide 30Rituximab 26Biopsy 23Specimen Handling 20Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 13Vincristine 11obinutuzumab 10Lenalidomide 10Etoposide 10Doxorubicin 10Bendamustine Hydrochloride 9pembrolizumab 7venetoclax 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5glofitamab 5acalabrutinib 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5copanlisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × ASTX-660 × 90 days × Clear all
NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
253 enrolled
GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡